Rosetta Genomics To Host Business Update Conference Call on April 10, 2013

  Rosetta Genomics To Host Business Update Conference Call on April 10, 2013

2012 Annual Report on Form 20-F Filed with SEC

PR Newswire

PHILADELPHIA, and REHOVOT, Israel, March 25, 2013

PHILADELPHIA,and REHOVOT, Israel, March 25, 2013 /PRNewswire/ --Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, today announced that following the close
of the U.S. stock market on Friday, March 22, 2013, the Company filed its
Annual Report on Form 20-F for the year ended December 31, 2012 with the U.S.
Securities and Exchange Commission ("SEC"). The Form 20-F includes audited
annual consolidated financial statements, as well as additional information
regarding the Company. The Form 20-F is available at and at 

Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics,
and Ron Kalfus, Chief Financial Officer of Rosetta Genomics, will host a
conference call on Wednesday, April 10, 2013 at 10:00 a.m. Eastern (7:00 a.m.
Pacific) to provide an update on the Company's business and respond to

Individuals interested in listening to the conference call may do so by
dialing (866) 239-5859, or for international callers (702) 495-1913. The
conference ID number is 27774171. The call is also being webcast, and can be
accessed on the investor relations section of the Company's Web site at and also at

A telephone replay will be available through April 16, 2013 by dialing (855)
859-2056 or for international callers (404) 537-3406, and entering the
Conference ID number 27774171. The webcast will be available for 30 days
following the completion of the call.

About miRview^® Products
miRview^® are a series of microRNA-based diagnostic products offered by
Rosetta Genomics. miRview^® mets² accurately identifies the primary tumor type
in primary and metastatic cancer including CUP. miRview^® meso diagnoses
mesothelioma, a cancer connected to asbestos exposure. miRview^® lung
accurately identifies the four main subtypes of lung cancer using small
amounts of tumor cells. miRview^® kidney accurately classifies the four most
common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. miRview^® tests are designed to provide
objective diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the miRview^®
mets² test, 60,000 from miRview^® meso, 54,000 from miRview^® kidney and
226,000 patients from miRview^® lung. The Company's assays are offered
directly by Rosetta Genomics in the U.S., and through distributors around the
world. For more information, please visit Parties
interested in ordering the test can contact Rosetta Genomics at (215) 382-9000
ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000 Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® product line is commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating
toRosetta'sstrategic plan,Rosetta's development or commercialization of
molecular diagnostics or therapeutics, the market acceptance of Rosetta's
miRview^®assays,particularly miRview^®mets^2, Rosetta's capitalization of
its microRNA platform, Rosetta's patent positionand Rosetta's development of
personalized medicine productsconstitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various important factors,
including those risks more fully discussed in the "Risk Factors" section of
Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012as
filed with the SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not be relied
upon as representing its views as of any subsequent date. Rosetta does not
assume any obligation to update any forward-looking statements unless required
by law.

Company Contact:
Rosetta Genomics
Ken Berlin, President & CEO
(215) 382-9000, ext.

Investor Contacts:
Anne Marie Fields
(212) 838-3777
Bruce Voss

SOURCE Rosetta Genomics Ltd.

Press spacebar to pause and continue. Press esc to stop.